Patents by Inventor Manshiu Leung

Manshiu Leung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination dosage form of a mu opioid receptor antagonist and an opioid agent
    Patent number: 11452723
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: September 27, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT
    Publication number: 20210161884
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Application
    Filed: February 8, 2021
    Publication date: June 3, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • Combination dosage form of a mu opioid receptor antagonist and an opioid agent
    Patent number: 10946009
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: March 16, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME
    Publication number: 20200361933
    Abstract: Salts, hydrates and solvates of Compound I and methods of making and using the same and related dosage forms thereof are disclosed.
    Type: Application
    Filed: February 1, 2019
    Publication date: November 19, 2020
    Inventors: Karthik Nagapudi, Yuan Liu, Shuai Wang, Wei Zhang, Fritz Blatter, Srikonda Sastry, Manshiu Leung, Ramachandran Radhakrishnan, Rajendra S. Tandale, Ludwig Pilsl, Roland Müller, Markus Frieser, Christine Czauderna, Lawrence Emerson Fisher
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20200323804
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20200147019
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: October 15, 2019
    Publication date: May 14, 2020
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT
    Publication number: 20190321350
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 24, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20190247345
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: December 10, 2018
    Publication date: August 15, 2019
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • Combination dosage form of a mu opioid receptor antagonist and an opioid agent
    Patent number: 10369142
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: August 6, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20180207117
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA analog prodrug sustained release oral dosage forms
    Patent number: 9949941
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: April 24, 2018
    Assignee: XENOPORT, INC.
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT
    Publication number: 20180050028
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 22, 2018
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20170071888
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 16, 2017
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT
    Publication number: 20160287573
    Abstract: The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
    Type: Application
    Filed: March 31, 2016
    Publication date: October 6, 2016
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Shaoling Li, Manshiu Leung, Hao Zhang, Venkat R. Thalladi, Yun Mo
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20150072004
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: November 4, 2014
    Publication date: March 12, 2015
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA analog prodrug sustained release oral dosage forms
    Patent number: 8906412
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: December 9, 2014
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20140302140
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA analog prodrug sustained release oral dosage forms
    Patent number: 8795725
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 5, 2014
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • Levodopa prodrug mesylate hydrate
    Patent number: 8722733
    Abstract: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.
    Type: Grant
    Filed: February 18, 2013
    Date of Patent: May 13, 2014
    Assignee: XenoPort, Inc.
    Inventors: Sami Karaborni, Manshiu Leung, Chen Mao, Venkat R. Thalladi
  • Levodopa prodrug mesylate hydrate
    Patent number: 8399513
    Abstract: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: March 19, 2013
    Assignee: XenoPort, Inc.
    Inventors: Sami Karaborni, Manshiu Leung, Chen Mao, Venkat Thalladi